炎性乳癌分子临床特征及治疗新进展  

Molecular clinical features and advances in treatment of inflammatory breast cancer

作　　者：陈靓昱 张悦[1] 张清媛[1] 

机构地区：[1]哈尔滨医科大学附属肿瘤医院,黑龙江哈尔滨150081

出　　处：《现代肿瘤医学》2016年第20期3331-3334,共4页Journal of Modern Oncology

摘　　要：炎性乳腺癌（inflammatory breast cancer,IBC）是一种发病率较低的特殊类型乳腺癌,仅占新诊断乳腺癌发病的1%~10%左右。因其侵袭能力强,疾病进展迅速,死亡率高,是乳腺癌中预后极差的类型之一。近年来,随着对乳腺癌分子分型的深入研究及多学科综合治疗的合理运用,IBC的治疗效果得到显著提高,患者生存时间明显延长。Inflammatory breast cancer （IBC） is a rare and special type of breast cancer. Reported studies showed that newly diagnosed of IBC account for one to 10 percent of all cases of breast cancer all over the world. Compared to other forms of breast cancer,inflammatory breast cancer was characterized by rapid proliferation,early metastatic de-velopment and poor prognosis. In recent years,with the research development of molecular subtyping of breast cancer and the rational application of multidisciplinary systemic therapy, the therapeutic efficacy of IBC has been significantly improved,and the survival of IBC patients has been significantly prolonged.

关 键 词：炎性乳癌 分子生物学 临床特征 新辅助化疗 综合治疗 

分 类 号：R737.9[医药卫生—肿瘤]